Skip to main content

SpeciCare Revolutionizes Gene Mapping

SpeciCare Revolutionizes Cancer Treatment with Tumor Cryopreservation and Gene Mapping


SpeciCare cryopreserves tumor tissue, enabling expanded therapy testing and empowering patients with personalized, future-ready treatment opportunities.

GAINESVILLE, GA, UNITED STATES, March 17, 2025 /EINPresswire.com/ -- SpeciCare, a pioneering healthcare company, is transforming cancer treatment by offering patients the ability to cryopreserve their tumor tissue for advanced genomic assays and more specific personalized therapies. Founded by a group of oncology specialists and advanced clinical researchers, SpeciCare aims to move beyond traditionally mass-administered cancer treatments to provide more effective individualized cancer care.

For decades, cancer treatment has relied on outdated tumor storage methods that provide limited views of the affected tissue—like trying to solve a city’s traffic crisis using a single aerial snapshot. But what if researchers had a live traffic feed instead? That’s what cryopreserving tumor tissue offers—an evolving, real-time window into cancer’s behavior, which is currently the missing component in bringing precision oncology care to the individual cancer patient.

By cryopreserving live tumor tissue, SpeciCare enables comprehensive genomic assays, which is not possible with the current FFPE method that destroys testable tissue. This necessary modification in the way that tissue is preserved and stored facilitates the development of tailored treatment plans for each patient. This individualized approach increases the efficacy of therapies and minimizes unnecessary side effects, offering patients a more targeted and effective treatment journey.

Access to their own cryopreserved tissue with Specicare allows patients to participate in multiple clinical trials simultaneously, without the need for additional surgeries or invasive procedures. This accessibility not only broadens treatment options but also accelerates the discovery of new therapies, benefiting not only the individual patient, but the broader cancer community as well.

The rise in cord blood banking popularity has highlighted the benefits of preserving personal biologics for future medical use. Similarly, tumor cryopreservation offers patients the opportunity to safeguard their unique cancer profile, ensuring access to cutting-edge treatments as they become available without added invasive procedures to acquire new tissue.

The time is right for the adoption of this much-improved method of tumor tissue management with the explosive addition of Artificial Intelligence (AI) to the healthcare space and specifically in the area of genomic assays. The union of Specicare’s access to the consented patient, the electronic medical record and the pristine tumor specimen is central to bringing AI successfully into the oncologic treatment arena.

The window between the initial suspicion of cancer and the biopsy is often narrow, making early intervention crucial. SpeciCare emphasizes the importance of involving preservation services as soon as cancer is suspected, ensuring that collection kits are available to surgeons before the biopsy. SpeciCare is committed to making advanced cancer treatments accessible to the individual patient and his or her family, with initial costs under $500. This affordability ensures that more patients can benefit from personalized therapies without financial strain.

Dr. Ken Dixon founded SpeciCare out of a desire to offer more to his patients. Frustrated with the limitations of traditional treatments, he envisioned a future where patients have control over their tumor tissue, unlocking new avenues for personalized care and improved outcomes.

Gene mapping, genetic markers, genome sequencing, linkage analysis, association mapping, quantitative trait loci (QTL), SNP genotyping, whole genome sequencing, genetic variation, gene localization, recombination frequency, chromosomal mapping, DNA sequencing, functional genomics, positional cloning, genetic linkage, genetic mapping techniques, molecular markers, bioinformatics in gene mapping, next-generation sequencing (NGS),

#GeneMapping, #GeneticMarkers, #GenomeSequencing, #LinkageAnalysis, #AssociationMapping, #QTL, #SNPGenotyping, #WholeGenomeSequencing, #GeneticVariation, #GeneLocalization, #RecombinationFrequency, #ChromosomalMapping, #DNASequencing, #FunctionalGenomics, #PositionalCloning, #GeneticLinkage, #MolecularMarkers, #Bioinformatics, #NextGenSequencing, #GenomicsResearch

International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: contact@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare

Comments

Popular posts from this blog

Fruitful innovation

Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adenine-to-thymine/ guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and A:T-to-T base substitutions, allowing for targeted genetic modifications. The research highlights the efficiency of these editors in generating specific mutations, such as a flowerless phenotype in ClFT (Y84H) mutant plants. This advancement not only enhances the understanding of gene function but also significantly improves molecular breeding, paving the way for more efficient watermelon crop improvement. Traditional breeding methods for watermelon often face challenges in achieving desired genetic traits efficiently and accurately. While CRISPR/Cas9 has provided a powerful tool for genome editing, its precision and scope are sometimes limited. These limitations highlight the need for more advanced gene-e...

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...

Genetics study on COVID-19

Large genetic study on severe COVID-19 Bonn researchers confirm three other genes for increased risk in addition to the known TLR7 gene Whether or not a person becomes seriously ill with COVID-19 depends, among other things, on genetic factors. With this in mind, researchers from the University Hospital Bonn (UKB) and the University of Bonn, in cooperation with other research teams from Germany, the Netherlands, Spain and Italy, investigated a particularly large group of affected individuals. They confirmed the central and already known role of the TLR7 gene in severe courses of the disease in men, but were also able to find evidence for a contribution of the gene in women. In addition, they were able to show that genetic changes in three other genes of the innate immune system contribute to severe COVID-19. The results have now been published in the journal " Human Genetics and Genomics Advances ". Even though the number of severe cases following infection with the SARS-CoV-...